October 9, 2023 06:44 AM EDTUpdated 11:20 AM

Updated: GSK taps Chinese partner to ramp up Shingrix sales in $3.05B deal, with option to expand to RSV

Amber Tong

GSK is tapping a heavyweight partner to co-promote its blockbuster shingles vaccine Shingrix in China — and locking in £2.5 billion ($3.05 billion) over the next …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Updated: GSK taps Chinese partner to ramp up Shingrix sales in $3.05B deal, with option to expand to RSV

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Up­dat­ed: GSK taps Chi­nese part­ner to ramp up Shin­grix sales in $3.05B deal, with op­tion to ex­pand to RSV

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Updated: GSK taps Chinese partner to ramp up Shingrix sales in $3.05B deal, with option to expand to RSV